Parkinson’s disease (PD) is a progressive brain disorder that causes unintended or uncontrollable movements, such as shaking, stiffness, and difficulty with balance and coordination. It has become the second most common neurodegenerative disease in the world. While the mechanism of the onset of Parkinson’s disease remains unclear, studies have shown that Parkinson’s disease is related to genetic factors, Preclinical CRO mitochondrial dysfunction, ubiquitin-proteasome system dysfunction, and excitotoxicity.
GemPharmatech has developed B6-hSNCA A53T and B6-Tfam-flox/Slc6a3-Cre models to study the mechanism of abnormal α-synuclein aggregation and mitochondrial dysfunction, respectively. These models can be used for drug screening, safety evaluation of therapeutic agents, and the study of pathogenesis in Parkinson’s disease.
Grip strength testing in B6-hSNCA A53T and B6-Tfam-flox/Slc6a3-Cre models
Fig 1. Grip strength test in B6-hSNCA A53T mice.
Limb strength of B6-hSNCA A53T mice was significantly lower than that of B6 control mice at 12 and 15 weeks of age. Data were expressed as mean ± SEM and evaluated using Paired T-Test. *: p-value ≤ 0.05，***: p-value ≤ 0.001, ****: p-value ≤ 0.0001.
Fig 2. Grip strength test in B6-Tfam-flox/Slc6a3-Cre mice.
At 10 weeks of age, the grip strength of B6-Tfam-flox/Slc6a3-Cre male and female mice was significantly lower than that of B6 control mice. Data were expressed as mean ± SEM and evaluated using Paired T-Test. ****: p-value ≤ 0.0001.
To learn more about PD models, please check:
B6-hSNCA A53T(T054329):https://en.gempharmatech.com/product/details100035_3733028.html
B6-Tfam-flox/Slc6a3-Cre(T053276):https://en.gempharmatech.com/product/details100035_3732872.html
